National trends and feasibility of a robotic surgical approach in the management of patients with inflammatory bowel disease

被引:5
|
作者
Radomski, Shannon N. [1 ]
Stem, Miloslawa [1 ]
Consul, Michael [1 ]
Maturi, Jay Rammohan [1 ]
Chung, Haniee [1 ]
Gearhart, Susan [1 ]
Graham, Ada [1 ,2 ]
Obias, Vincent J. [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Colorectal Res Unit, Baltimore, MD 21205 USA
[2] Johns Hopkins Med, Natl Capital Reg, 10215 Fernwood Rd,Suite 630, Bethesda, MD 20817 USA
来源
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES | 2023年 / 37卷 / 10期
关键词
Robotic surgery; Crohn's disease; Ulcerative colitis; Inflammatory bowel disease; MINIMALLY INVASIVE SURGERY; PROCTECTOMY; PREVALENCE; OUTCOMES;
D O I
10.1007/s00464-023-10333-1
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Research on the utilization of robotic surgical approaches in the management of inflammatory bowel disease (IBD) is limited. The aims of this study were to identify temporal trends in robotic utilization and compare the safety of a robotic to laparoscopic operative approach in patients with IBD.Methods Patients who underwent minimally invasive surgery (MIS) for IBD were identified using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database (2013-2021). Temporal trends of robotic utilization were assessed from 2013 to 2021. Primary (30-day overall and serious morbidity) and secondary (unplanned conversion to open) outcomes were assessed between 2019 and 2021, when robotic utilization was highest. Multivariable logistic regression was performed.Results The use of a robotic approach for colectomies and proctectomies increased significantly between 2013 and 2021 (p < 0.001), regardless of disease type. A total of 6016 patients underwent MIS for IBD between 2019 and 2021. 2234 (37%) patients had surgery for UC [robotic 430 (19.3%), lap 1804 (80%)] and 3782 (63%) had surgery for CD [robotic 500 (13.2%), lap 3282 (86.8%)]. For patients with UC, there was no difference in rates of overall morbidity (22.6% vs. 20.7%, p = 0.39), serious morbidity (11.4% vs. 12.3%, p = 0.60) or conversion to open (1.5% vs. 2.1%, p = 0.38) between the laparoscopic and robotic approaches, respectively. There was no difference in overall morbidity between the two groups in patients with CD (lap 14.0% vs robotic 16.4%, p = 0.15), however the robotic group exhibited higher rates of serious morbidity (7.3% vs. 11.2%, p < 0.01), shorter LOS (3 vs. 4 days, p < 0.001) and lower rates of conversion to an open procedure (3.8% vs. 1.6%, p = 0.02). Adjusted analysis showed similar results.Conclusion The use of the robotic platform in the surgical management of IBD is increasing and is not associated with an increase in 30-day overall morbidity compared to a laparoscopic approach.
引用
收藏
页码:7849 / 7858
页数:10
相关论文
共 50 条
  • [11] Perceptions on the surgical treatment of inflammatory bowel disease in Spain. Results of a national survey
    Sanchez-Guillen, Luis
    Blanco-Antona, Francisco
    Millan-Scheiding, Monica
    CIRUGIA ESPANOLA, 2016, 94 (10): : 560 - 568
  • [12] Nutritional Support of Surgical Patients with Inflammatory Bowel Disease
    Wagner, I. Janelle
    Rombeau, John L.
    SURGICAL CLINICS OF NORTH AMERICA, 2011, 91 (04) : 787 - +
  • [13] Advances in the surgical management of inflammatory bowel disease
    Nandivada, Prathima
    Poylin, Vitaly
    Nagle, Deborah
    CURRENT OPINION IN GASTROENTEROLOGY, 2012, 28 (01) : 47 - 51
  • [14] National trends and inpatient outcomes of inflammatory bowel disease patients with concomitant chronic liver disease
    Nguyen, Douglas L.
    Bechtold, Matthew L.
    Jamal, Mohammad Mazen
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2014, 49 (09) : 1091 - 1095
  • [15] Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease
    Orlando, Ambrogio
    Guglielmi, Francesco William
    Cottone, Mario
    Orlando, Emanuele
    Romano, Claudia
    Sinagra, Emanuele
    DIGESTIVE AND LIVER DISEASE, 2013, 45 (12) : 986 - 991
  • [16] Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
    Whitlock, Scott M.
    Enos, Clinton W.
    Armstrong, April W.
    Gottlieb, Alice
    Langley, Richard G.
    Lebwohl, Mark
    Merola, Joseph F.
    Ryan, Caitriona
    Siegel, Michael P.
    Weinberg, Jeffrey M.
    Wu, Jashin J.
    Van Voorhees, Abby S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (02) : 383 - 394
  • [17] Racial disparities in surgical outcomes of patients with Inflammatory Bowel Disease
    Montgomery, Samuel R., Jr.
    Butler, Paris D.
    Wirtalla, Chris J.
    Collier, Karole T.
    Hoffman, Rebecca L.
    Aarons, Cary B.
    Damrauer, Scott M.
    Kelz, Rachel R.
    AMERICAN JOURNAL OF SURGERY, 2018, 215 (06) : 1046 - 1050
  • [18] Surgical management of inflammatory bowel disease
    Robert R. Cima
    John H. Pemberton
    Current Treatment Options in Gastroenterology, 2001, 4 (3) : 215 - 225
  • [19] The management of immunosuppression in patients with inflammatory bowel disease and cancer
    Bernheim, Oren
    Colombel, Jean-Frederic
    Ullman, Thomas A.
    Laharie, David
    Beaugerie, Laurent
    Itzkowitz, Steven H.
    GUT, 2013, 62 (11) : 1523 - 1528
  • [20] Evaluation of Racial/Ethnic Disparities in the Surgical Management of Inflammatory Bowel Disease
    Ore, Ana Sofia
    Vigna, Carolina
    Fabrizio, Anne
    Messaris, Evangelos
    JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (12) : 2559 - 2568